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ABSTRACT
In the last two years, a substantial increase in the number of malaria vivax cases has 
occurred in the Brazilian Amazon basin. The adequate exposure of hypnozoites to primaquine 
is a matter of interest as these dormant forms are responsible for the maintenance or even the 
increase of malaria burden in endemic areas. The aim of this study was to estimate the levels 
of primaquine and carboxyprimaquine in whole blood samples of patients with P. vivax treated 
with chloroquine and an abbreviated regimen of primaquine (0.5 mg/kg/d for 7 days), with 
adequate clinical and parasitological outcomes after 180 days of follow-up . A total of 40 
male patients met the criteria for inclusion in the study. Primaquine and carboxyprimaquine 
were measured by high-performance liquid chromatography. The levels of primaquine in 
whole blood samples ranged from 40-238 ng/mL, 42-196 ng/mL and 42-150 ng/mL on 
days 1, 3 and 7. The levels of carboxyprimaquine in whole blood samples ranged from 
87-234 ng/mL, 96-252 ng/mL and 74-448 ng/mL on days 1, 3 and 7. These data provide a 
reliable estimation of exposure of the infecting parasite to primaquine. Based on the regional 
pattern of relapse, the estimated blood levels of primaquine can be considered effective 
against hypnozoites of the local circulating strains of P. vivax. 
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INTRODUCTION
In the last two years, a substantial increase in malaria vivax burden occurred 
in several municipalities of the Brazilian Amazon basin1,2. The reasons for the 
unexpected increase of cases are unclear, and health authorities are investigating 
several factors, including the relapse of hypnozoites due to resistance or to reduced 
sensitivity of P. vivax strains to primaquine, as well as the inadequate exposure to 
this drug due to low-quality of commercial formulations, use of sub-therapeutic 
doses, non-compliance with the prescribed regimen and variations in the kinetic 
disposition of primaquine3-7.
Despite the fact that tafenoquine has been approved in July 2018 by the United 
States’ Food and Drug Administration for the radical cure of vivax infections in patients 
aged 16 and older, primaquine is still the only available drug to eliminate hypnozoites 
from the human host in several endemic areas8. Health authorities recommend the 
supervised administration of this drug. However, there are logistic difficulties in the 
riverside communities of the Amazon basin. Compliance with prescribed regimen 
is also a matter of interest in this endemic setting. A feasible method to assess the 
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exposure of the infecting parasite population to antimalarial 
drugs is the measure of their levels in biological fluids9. 
There are limitations to interpret primaquine blood levels 
in studies of therapeutic efficacy including the drug’s short 
half-life, pharmacological and toxicological effects due to 
hydroxylated metabolites, and the fact that the therapeutic 
efficacy depends on the amount of drug that reaches 
hepatocytes, which is related to the total dose administered, 
but not with frequency or duration of exposure. Finally, 
there is a high variation in the pharmacokinetics of the drug 
amongst and in individuals10-14.
The measurement of blood levels of primaquine and 
its main metabolite only once during treatment may give 
a reliable assessment of exposure of the infecting parasite 
population to the drug. Moreover, the association of drug 
blood levels with clinical and parasitological outcomes 
provides insight on the effectiveness of blood levels of 
primaquine against hypnozoites. To date, the exposure 
to primaquine and its carboxyl metabolite has not been 
assessed in malaria patients in the Brazilian Amazon basin. 
Therefore, the aim of this study was to estimate the levels of 
primaquine and carboxyprimaquine in whole blood samples 
of patients with malaria vivax treated with chloroquine and 
an abbreviated regimen of primaquine (0.5 mg/kg/d for 7 d), 
with adequate clinical and parasitological outcomes after a 
180 days of follow-up. 
MATERIAL AND METHODS
Study site and patients
This study is a one-arm prospective evaluation of 
exposure to primaquine during treatment of malaria vivax 
carried out from January 2015 to December 2016 at the 
Unidade Basica de Saude (Basic Health Unit) of Anajas, 
PA, a municipality in Marajo Island in the Brazilian Amazon 
basin (0°59’21” S and 49°56’24” W). The transmission of the 
disease in Anajas is intense with some seasonal variation and 
P. vivax accounts for approximately 85% of cases. In the last 
years, the municipality reported the highest number of cases 
to the National Surveillance System, in the State of Para.
Inclusion criteria for enrollment in the study were: adult 
male >18 years old with mono-infection by P. vivax detected 
by microscopy, axillary temperature above 37 ºC or history 
of fever during the past 24 h and being able to swallow the 
oral medication. The exclusion criteria included patients 
with signs and symptoms of severe disease (jaundice, 
pulmonary or renal impairment, severe anemia, altered levels 
of consciousness), glucose-6-phosphate dehydrogenase 
deficiency, mixed infection detected by microscopy, 
parasitemia over 5%, overweight (or underweight), 
presence of fever due to diseases other than malaria, or other 
known underlying chronic or severe diseases, history of 
hypersensitivity reaction to chloroquine or primaquine and 
use of antimalarial drugs in the previous 90 days. 
Treatment and follow-up
Each patient received multiple oral doses regimen of 
chloroquine (10 mg/kg on day 0 and 7.5 mg/kg on days 1 
and 2) co-administered with primaquine (0.5 mg/kg/d for 
7 days, as 13.2mg of primaquine phosphate tablets)8. The 
primaquine dose was adjusted according to body weight. 
All doses of medicines were administered under the 
supervision of a qualified member of the research team. The 
study patients were observed for 30 min after the medicine 
administration for the the observation of adverse reactions 
or vomiting. Patients were requested to return for blood 
sampling and clinical evaluation on days 1, 3, 7, 14, 21 
and 28. Then, the study patients were monitored by passive 
surveillance at the health facility for a period of 180 days. 
Moreover, records from the National Malaria Database 
(SIVEP-Malaria) were investigated to identify any other 
malaria test performed during the study period in any of the 
study patients. Clinical and parasitological outcomes were 
based on the standardized WHO protocols15.
Sample size
The sample size was based on previous studies of 
efficacy conducted in this endemic setting, which has 
reported a failure rate of about 2% to the standard treatment 
of malaria vivax, with a confidence level of 95% and 
precision of 5%. Thus, a minimum sample of 30 patients 
was required for the study2,7,15,16. 
Evaluation of efficacy
The parasite count was performed in Giemsa-stained 
thick films every day until the negativity of parasitemia, and 
on days 1, 3, 7, 14, 21 and 28. An experienced microscopist 
examined the blood films using 100X (oil immersion) 
objectives. The parasite density was expressed as the 
number of parasites per µL of blood, estimated according 
to the number of parasites per 200 white blood cells, 
considering a total white blood cell count of 8,000. The 
limit of detection of the parasites was 40/µL15. 
Blood sample collection
Venous blood samples (4 mL) were taken from 
each patient for primaquine and carboxyprimaquine 
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measurements at baseline (D0) and on days 1, 3 and 7. All 
blood samples were collected approximately 3 h after the 
primaquine intake. Blood samples were immediately stored 
at -80 ºC until analysis. 
Measurement of primaquine and carboxyprimaquine
Primaquine and carboxyprimaquine were measured by 
a reversed-phase HPLC system with a diode array detector 
(Flexar System - Perkin Elmer Inc., Boston, MA, USA) after 
liquid-liquid extraction from the whole blood samples with 
methyl tert-butyl ether at pH 3. The separation was carried out 
in a reversed-phase column RP-18, 15 cm × 4 mm i.d. (Perkin-
Elmer Inc.). The mobile phase consisted of acetonitrile- 
phosphate buffer, pH 3.5 (30:70) eluate at 1.0 mL/min. 
Analytes were recorded at 254 nm. Quinine (1.0 µg/mL) was 
used as an internal standard17. The method was linear in the 
range from 50 ng/mL to 900 ng/mL. The limit of detection 
was 20 ng/mL and the limit of quantification was 30 ng/mL 
for both analytes. The mean coefficients of variation within 
a day and day-to-day were 12.3% and 16.1%, respectively. 
The mean recovery of primaquine from whole blood was 
87.3%. For carboxyprimaquine, the mean coefficients of 
variation within a day and day-to-day were 14.1% and 
17.4%, respectively. The mean recovery was 88.5%. The 
stability of primaquine (100 ng/mL) and carboxyprimaquine 
in whole blood samples were tested by spiking the analytes 
in the biological matrix, which was stored for 120 days at 
-80 oC. There were no significant interferences of mefloquine, 
chloroquine, desethyl-chloroquine, carboxy-mefloquine, 
and acetaminophen in the detection of both analytes.
Data analysis
Data were analyzed by non-parametric methods. The 
Kruskal-Wallis H-test was used to compare the levels of 
primaquine and carboxyprimaquine amongst the days 
of study. All p-values were two-tailed, and p < 0.05 was 
considered significant. Statistical analyses were performed 
with STATISTICA software package (Version 7.0, Stat Soft 
Inc., 2004, Tulsa, USA).
Ethical statement
The ethics committee of the Instituto de Ciencias da 
Saude (Health Science Institute) of the Federal University 
of Para has reviewed and approved the study protocol 
(CONEP Nº 2.770.805). All patients enrolled in the study 
were informed about the goals, as well as the risks and 
benefits of the study. All patients provided written informed 
consent before entering the study.
RESULTS
A total of 40 patients were recruited for the study and 
140 whole blood samples were collected and analyzed for 
primaquine and carboxyprimaquine. A total of 20 blood 
samples were not analyzed due to the loss of patients’ follow 
up. The baseline characteristics of patients are presented 
in Table 1.
Study patients showed low parasite density as well as 
mild signs and symptoms of malaria. There were no reports 
of serious adverse reactions or vomiting during treatment. 
The average time of parasite clearance from the peripheral 
blood was 36 h. The local health facility and the Malaria 
National Surveillance System did not report reappearance 
of parasites in the blood of study patients in the 180 days 
of follow-up. 
The average time for blood sampling was 3.0 (0.5) h. 
All patients had undetectable levels of both primaquine 
and carboxyprimaquine on day 0. The levels of primaquine 
in whole blood samples ranged from 40-238 ng/mL, 
42-196 mg/mL and 42-150 ng/mL on days 1, 3 and 
7, respectively. There was no significant difference in 
blood levels of primaquine amongst the days of the study 
(H=1.05; p=0.589). The levels of carboxyprimaquine 
ranged from 87-234 ng/mL, 96-252 ng/mL and 
74-448 ng/mL on days 1, 3 and 7, respectively. The levels 
of carboxyprimaquine were similar between days 1 and 3, 
but they were significantly lower than on day 7 (H=13.27; 
p=0.001) (Table 2).
Table 1 - Baseline characteristics of patients
Characteristic Patients (n=40)
Ages, years 29 (16)
Weight, kg 63(12)
Parasite count on D0, mm3 1920(1438)
Parasite clearance, h 36 (12)
Fever clearance, h 18(12)
Previous episodes of infection, % 100
Hemoglobin, g/dL 11.4 (3.1)
Hematocrit, % 36(12.1)
Erythrocytes count, 106  4.3 (0.62)
White blood cells, mm3 6,180 (1210)
Creatinine, mg/dL 0.6(0.3)
Aspartate aminotransferase, U/I 28(13)
Alanine aminotransferase, U/I 43(12)
Results are expressed as mean (standard deviation) and 
percentage
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DISCUSSION
Primaquine is used to eliminate hypnozoites from the 
human host, which are responsible for the relapses weeks 
to months after the primary infection, contributing to the 
malaria vivax burden in the Amazon basin12,18. Relapses 
may occur as early as 16 days up to 3 years after the initial 
infection, even if the blood stage was adequately treated19. 
In the study, the follow-up was adapted to the regional 
pattern of relapse of P. vivax in Brazil, of about three 
months after the initial attack20-22. The abbreviated regimen 
of primaquine was recommended by the Brazilian Malaria 
Control Programsince the 1990s to improve the tolerability 
and the compliance with treatment23.
Several confounding factors were controlled in the study, 
allowing the reliable estimation of exposure of the parasites 
to primaquine, such as the supervised administration of the 
drug, the validation parameters of the analytical method 
for both compounds were adequate and the time of blood 
sampling was carefully monitored. Moreover, the use of 
whole blood samples as the biological matrix was based 
on previous studies that reported a similar concentration-
time profile of both, the parent compound and the carboxyl 
metabolite in whole blood and in plasma samples of healthy 
volunteers9,14,24. 
The days and time for blood sampling were based 
on the pharmacokinetic parameters of primaquine 
and carboxyprimaquine. The parent drug is virtually 
completely absorbed, has a plasma elimination half-life 
of 4-9 h, peak of plasma concentrations are reached within 
1-3 h, and it does not accumulate in the course of chronic 
doses of 15 mg. Urinary excretion of primaquine is low, 
with most of the dose recovered as metabolites13,14,24,25. 
The levels of primaquine were similar amongst the days of 
study, corroborating the lack of significant accumulation of 
the drug in body components. The highest concentrations 
were found on day 3, in agreement with the potential 
changes in pharmacokinetic parameters of the drug due to 
concurrent administration of chloroquine. Moreover, the 
parasites in blood and the change of parasites clearance 
under chronic doses may interfere with blood levels of 
primaquine14,17,24-27.
Despite the high variation in blood levels of primaquine 
among the participants of the study, the normalization of 
data by dosing regimen provided similar results to those 
reported in healthy volunteers and in patients with malaria 
vivax from different endemic areas, such as Thailand and 
India13,14,24-26.
Carboxyprimaquine is the major metabolite generated 
via metabolism by MAO-A13,27. The metabolite does not 
show pharmacological or toxicological activities13,28,29.
There are significant differences in the pharmacokinetic 
profile of the metabolite compared to the parent drug. 
Carboxyprimaquine has a longer plasma elimination half-
life (~15 h), peak of plasma levels are reached within 4-12 h 
and may be up to 10 times higher than the parent compound, 
the area under the curve is considerably greater than the 
parent drug, and its more polar characteristic suggests a 
limited distribution with high levels in plasma water13,30. 
Based on pharmacokinetic parameters, carboxyprimaquine 
may be considered a potential candidate for the assessment 
of exposure to primaquine. 
The main limitation of the study was the probable 
underestimation of carboxyprimaquine levels as blood 
sampling was based on time to reach plasma peak 
concentrations of primaquine (3±1 h), rather than the 
carboxyl metabolite (7±4 h)13,30.
Overall, the levels of primaquine and carboxyprimaquine 
agreed with the pharmacokinetic profile of both compounds 
reported in studies performed in different endemic settings. 
Data provided a reliable estimation of exposure of the 
infecting parasite population to primaquine during treatment 
of malaria vivax in a population from the Brazilian Amazon 
basin which can be useful to strengthen the ongoing 
surveillance of primaquine efficacy in this endemic setting. 
Based on the regional pattern of relapse, blood levels of 
primaquine found in this study were effective against local 
circulating P. vivax strains.
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D7 70 (63- 99.8) 231 (170-284)
Results are expressed as median and interquartile range. 
nd = not detected
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